Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Compass Therapeutics, Inc. has received a consensus rating of "Moderate Buy" from analysts, with one sell recommendation and nine buy recommendations.
• The average target price for the stock among brokers is $13.10, with notable price targets including $32.00 and $10.00 from different research firms.
• As of the latest reports, Compass Therapeutics' stock has decreased by 5.8% and has a market cap of $589.07 million with a current share price of $4.26.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eleven brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $13.10.

Several research firms have recently commented on CMPX. Guggenheim boosted their price target on Compass Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Tuesday, August 12th. Lifesci Capital began coverage on Compass Therapeutics in a research report on Monday, October 6th. They issued an "outperform" rating and a $10.00 price target for the company. D. Boral Capital reissued a "buy" rating and issued a $32.00 price target on shares of Compass Therapeutics in a research report on Tuesday, August 12th. Compass Point set a $10.00 price target on Compass Therapeutics in a research report on Monday, October 6th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CMPX. Vontobel Holding Ltd. bought a new position in shares of Compass Therapeutics in the 1st quarter worth $57,000. Bank of New York Mellon Corp increased its position in Compass Therapeutics by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 243,565 shares of the company's stock valued at $463,000 after buying an additional 5,590 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Compass Therapeutics by 4.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 297,880 shares of the company's stock valued at $566,000 after buying an additional 11,689 shares in the last quarter. Deutsche Bank AG acquired a new position in Compass Therapeutics during the 1st quarter valued at about $194,000. Finally, Nuveen LLC acquired a new position in Compass Therapeutics during the 1st quarter valued at about $579,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Stock Down 5.8%

Shares of NASDAQ CMPX opened at $4.26 on Friday. The business has a fifty day simple moving average of $3.52 and a two-hundred day simple moving average of $2.74. The firm has a market cap of $589.07 million, a PE ratio of -9.47 and a beta of 1.48. Compass Therapeutics has a twelve month low of $1.27 and a twelve month high of $4.86.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). On average, research analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.